Promising drug cocktail takes on deadly brain cancer
NCT ID NCT03535350
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 30 times
Summary
This early-phase trial tests whether adding the drug ibrutinib to standard radiation and chemotherapy is safe for people with a newly diagnosed aggressive brain cancer called glioblastoma. The study includes 36 participants and looks at different doses based on a specific genetic marker (MGMT). The main goal is to find the highest safe dose and monitor side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio, 44195, United States
Conditions
Explore the condition pages connected to this study.